Skip to content
The GLP-1 Verdict
Menu

Head-to-head verdict

CoreAge Rx vs Peter MD

Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.

Published by The GLP-1 Verdict

Pricing sources checked: CoreAge Rx: August 2026 · Peter MD: October 2026

WinnerGrade A · #1

CoreAge Rx

The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.

Visit CoreAge Rx
vs
Grade C · #433

Peter MD

A physician-prescribed telehealth brand with tiered semaglutide pricing and a discounted tirzepatide first month — restrictions vary by treatment, excluding several states, and its own marketing page understates them.

Visit Peter MD

The verdict

Winner: CoreAge Rx

CoreAge Rx takes it with a higher Verdict Score — 94/100 to 52/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Peter MD still earns its place — patients outside the excluded states who want tiered semaglutide pricing or a discounted tirzepatide first month from a physician-founded telehealth brand.

The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.

Factor by factor

Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.

92Real-world results58
97Price honesty42
96Prescriber access60
88Formulary choice45
95Cancellation fairness50
93Member support55

Price, coverage & features

MetricCoreAge RxPeter MD
Verdict Score94/10052/100
GradeAC
Semaglutide$99/mo$149/mo first-time (3 months billed upfront), $139/mo returning (6 months billed upfront)
Tirzepatide$149/mo$149 first month, then $249/mo thereafter, billed quarterly
CoverageAll 50 statesMost states — excludes AL, ID and up to 5 more depending on treatment
Brand-name accessCompounded onlyCompounded only
Oral / sublingualNoNo

CoreAge Rx

What we like

  • Flat, all-in monthly price with no intro-rate step-ups after month one
  • Both compounded semaglutide and tirzepatide on one account
  • Available in all 50 states
  • Straightforward, low-friction cancellation

The caveats

  • Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
  • No FDA-approved brand-name option (compounded only)
  • Does not yet publicly name its 503A/B pharmacy partner

Peter MD

What we like

  • Physician-prescribed telehealth model, founded 2021, headquartered in Miami, FL
  • Semaglutide is priced in two published tiers, each shown with its upfront total ($447 for first-time patients, $834 for returning patients)
  • Tirzepatide's discounted first month ($149) is stated up front rather than buried in fine print

The caveats

  • The affiliate program's own disclosed restricted-state list is broader than the customer-facing pricing pages: tirzepatide is additionally excluded in AR, CA, MI, NC and TX beyond the AL/ID the marketing page names, and the two disclosures do not agree
  • Tirzepatide's price nearly doubles after the first month, from $149 to $249/mo, billed quarterly
  • Semaglutide is sold combined with B12 as "GLP1 + B12," not offered as a standalone prescription
  • No oral or sublingual option — injectable only
  • Customer reviews are mixed

Our pick — visit

Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.

Visit CoreAge Rx Read the full CoreAge Rx review →

Also worth a look

Patients outside the excluded states who want tiered semaglutide pricing or a discounted tirzepatide first month from a physician-founded telehealth brand.

Visit Peter MD Read the full Peter MD review →

Keep comparing

Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for Peter MD does the reverse.

Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.

Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.